Single Nucleotide Polymorphism (SNP) Genotyping Market Report 2026

Single Nucleotide Polymorphism (SNP) Genotyping Market Overview

• Single Nucleotide Polymorphism (SNP) Genotyping market size has reached to $12.34 billion in 2025 • Expected to grow to $29.74 billion in 2030 at a compound annual growth rate (CAGR) of 19.3% • Growth Driver: The Rising Role Of SNP Genotyping In Chronic Disease Management • Market Trend: Revolutionizing Coronary Heart Disease Diagnosis With AI And Biomarkers • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Single Nucleotide Polymorphism (SNP) Genotyping Market?

Single nucleotide polymorphism (SNP) genotyping refers to a procedure that locates and describes genetic variants at the level of specific DNA nucleotides. It identifies individual SNPs, which are single-base changes in DNA sequences, and it is essential for understanding the genetic variations linked to diseases, traits, and population studies. The main products of single nucleotide polymorphism (SNP) genotyping are consumables, instruments, and services. Consumables refer to commodities that people and businesses consume or use up and need to be replaced regularly, such as food and home supplies. The various technologies include TaqMan SNP genotyping, mass array SNP genotyping, SNP gene chip arrays, and others used in various applications such as animal genetics, plant improvement, diagnostic research, pharmaceuticals and pharmacogenomics, agricultural biotechnology, and others.

What Is The Single Nucleotide Polymorphism (SNP) Genotyping Market Growth Forecast?

The single nucleotide polymorphism (snp) genotyping market size is expected to see rapid growth in the next few years. It will grow to $29.74 billion in 2030 at a compound annual growth rate (CAGR) of 19.3%. The growth in the forecast period can be attributed to development of high-throughput SNP platforms, increasing adoption in personalized medicine, integration with AI for predictive analysis, expansion into clinical diagnostics, growth in agricultural genomics applications. Major trends in the forecast period include integration with pharmacogenomics, growth in disease risk prediction, increasing use in agriculture and animal breeding, adoption of microarray-based genotyping, rise in point-of-care SNP testing.

What Is The Driver Of The Single Nucleotide Polymorphism (SNP) Genotyping Market?

The increasing burden of chronic conditions is expected to propel the growth of the single nucleotide polymorphism (SNP) genotyping market going forward. Chronic conditions are problems that last a year or longer, necessitating continuing medical care, restricting everyday activities, or both. Single-nucleotide polymorphism (SNP) genotyping is essential for identifying genetic predispositions and promoting personalized medicine due to the increased prevalence of chronic diseases. For instance, in April 2025, according to the Centers for Disease Control and Prevention (CDC), a US-based federal agency. in 2023, approximately 194 million U.S. adults, or 76.4%, reported having at least one chronic condition. The prevalence was 59.5% among young adults, 78.4% among midlife adults, and 93.0% among older adults. Therefore, the increasing burden of chronic conditions drives the growth of the single nucleotide polymorphism (SNP) genotyping systems market.

Key Players In The Global Single Nucleotide Polymorphism (SNP) Genotyping Market

Major companies operating in the single nucleotide polymorphism (snp) genotyping market are Thermo Fischer Scientific Inc, Danaher Corporation, Roche Diagnostics Corporation, GE HealthCare Technologies Inc, Eurofins Genomics LLC, Beckman Coulter Inc, Bio-Rad Laboratories Inc, Qiagen N.V, Sigma-Aldrich Corporation, Agilent Technologies Inc, PerkinElmer Inc, Illumina Inc, Promega Corporation, GenScript Biotech Corporation, Integrated DNA Technologies Inc, LGC Ltd, Sequenom Inc, Fluidigm Corporation, Oxford Gene Technology, Affymetrix Inc, PREMIER Biosoft International Inc, Rubicon Genomics, Xcelris Genomics, Douglas Scientific LLC, Golden Helix Inc

Global Single Nucleotide Polymorphism (SNP) Genotyping Market Trends and Insights

Major companies operating in the single nucleotide polymorphism (SNP) genotyping market are developing biomarkers that are useful in coronary heart disease detection to increase their profitability in the market. Single nucleotide polymorphism (SNP) biomarkers associated with coronary heart disease (CHD) detection are specific genetic variations that have been identified through genomic research and are linked to an increased risk or susceptibility to coronary heart disease. For instance, in February 2023, Cardio Diagnostics, a US-based biotechnology company launched PrecisionCHD. PrecisionCHD is an AI-driven blood test that utilizes a combination of epigenetic (DNA methylation) and genetic (single nucleotide polymorphism) biomarkers to detect CHD. The test employs a machine-learning model to achieve over 75% sensitivity for both genders, providing a non-invasive option for in-office or at-home blood sample collection. This eliminates the necessity for traditional tests like stress tests, ensuring objectivity by relying solely on biomarkers, rather than self-reported patient data.

What Are Latest Mergers And Acquisitions In The Single Nucleotide Polymorphism (SNP) Genotyping Market?

In December 2023, Neogen Corporation, a US-based food safety company that specializes in a variety of genomic technologies, particularly in single nucleotide polymorphism (SNP) genotyping, partnered with TerraNova Equestrian Center. The partnership aims to enhance biosecurity measures at TerraNova Equestrian Center by utilizing Neogen's advanced cleaning and disinfectant solutions. This collaboration focuses on safeguarding the health of horses and their owners while promoting a safe environment for equestrian competitions. TerraNova Equestrian Center is a US-based company that provides a premier facility for riders and horses.

What Defines the Single Nucleotide Polymorphism (SNP) Genotyping Market?

The single nucleotide polymorphism (SNP) genotyping market includes revenues earned by providing sample collection, DNA extraction, high-resolution melting analysis, and related next-generation sequencing. The market value includes the value of related goods sold by the service provider or included within the service offering. The single nucleotide polymorphism (SNP) genotyping market consists of sales of mass spectrometry-based SNP genotyping and allele-specific PCR. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Single Nucleotide Polymorphism (SNP) Genotyping Market Report 2026?

The single nucleotide polymorphism (snp) genotyping market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the single nucleotide polymorphism (snp) genotyping industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.